Surface expression of enzyme in gene directed prodrug therapy

• US 6,025,340 A
• Filed: 01/31/1997
• Issued: 02/15/2000
• Est. Priority Date: 07/27/1994
• Status: Expired due to Term

• Current Assignee: Cancer Research Campaign Technology Ltd (Cancer Research UK)
• Original Assignee: Cancer Research Campaign Technology Ltd (Cancer Research UK)
• Inventors: Marais, Richard, Springer, Caroline Joy
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): Nguyen, Dave Trong
• Application Number:
  US08/776,251
• Time in Patent Office: 1,110 Days
• Field of Search: 514/44, 435/320.1, 435/375, 435/172.1, 435/172.3, 435/69.1, 435/69.7, 435/69.8, 435/212, 435/220, 536/23.2, 536/23.4, 536/23.7, 536/24.1, 424/94.1, 424/94.63, 935/52, 935/62, 935/66, 935/48, 935/51, 935/455
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 38/4813 Exopeptidases (3.4.11. to 3.4.19)
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/665 the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
• CPC Class Codes: A61K 47/67 Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
• CPC Class Codes: A61K 47/6899 Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C12N 9/12 transferring phosphorus containing groups, e.g. kinases (2.7)
• CPC Class Codes: C12N 9/48 acting on peptide bonds (3.4)

Abstract

The invention provides a two component system for use in association with one another comprising:

(a) a vector capable of expressing an enzyme at the surface of a cell; and

(b) a prodrug which can be converted into an active drug by said enzyme, useful in the treatment of tumours.

Claims

1. A product comprising two components for use in association with one another comprising:

(a) a vector comprising a eukaryotic promoter operably linked to a gene, said gene comprising a nucleic acid sequence encoding a bacterial carboxypeptidase G which has been altered at one or more glycosylation sites to prevent glycosylation at said site or sites together with a signal sequence, wherein upon expression of said gene in a eukaryotic tumor cell said signal sequence directs and tethers said bacterial carboxypeptidase to the plasma membrane of said tumor cell; and

(b) a prodrug which can be converted into an active drug by said bacterial carboxypeptidase G.

2. A product according to claim 1 wherein the bacterial carboxypeptidase G is carboxypeptidase CPG2.

3. A product according to claim 1 wherein the prodrug is a nitrogen mustard prodrug.

4. A product according to claim 1 wherein the signal sequence comprises a nucleic acid sequence encoding a signal peptide of a transmembrane receptor kinase.

5. A product according to claim 1 wherein said promoter is expressed in a tissue restricted manner.

6. A product according to claim 5 wherein the promoter is a c-erbB2 promoter.

7. A product according to claim 2 wherein one or more of the residues Asn 222, Asn 264 and Asn 272 of the CPG2 have been substituted.

8. A product according to claim 2 wherein the residues 222 and 272 have been altered to glutamine and residue 266 altered to leucine.

9. A bacterial carboxypeptidase G which comprises a substitution, deletion or insertion at one or more glycosylation sites so as to prevent glycosylation at said site while retaining carboxypeptidase activity.

10. A carboxypeptidase according to claim 9 which is CPG2.

11. A carboxypeptidase according to claim 10 wherein residues 222 and 272 have been altered to glutamine and residue 266 has been altered to leucine.

12. A carboxypeptidase according to claim 10 in which one or more of the residues Asn 222, Asn 264 and Asn 272 have been substituted.

13. A vector comprising a nucleic acid sequence encoding the bacterial carboxypeptidase G of claim 9.

14. A vector according to claim 13 which further comprises a signal sequence capable of directing expression of the carboxypeptidase to the surface of a mammalian cell.

15. A vector according to claim 14 the signal sequence is a signal peptide of a transmembrane receptor kinase.

21. A method of expressing a bacterial carboxypeptidase G in a eukaryotic cell, said bacterial carboxypeptidase G comprising a substitution deletion or insertion at one or more glycosylation sites so as to prevent glycosylation at said site while retaining carboxypeptidase activity, said method comprising culturing a eukaryotic cell which has been transformed with a vector according to claim 13 under conditions whereby said bacterial carboxypeptidase is expressed.

22. The method according to claim 21 further comprising transforming said eukaryotic cell into said vector prior to said culturing.

16. A method of treating a tumor in a patient in need of treatment which method comprises administering to said patient an effective amount of a vector comprising a eukaryotic promoter operably linked to a gene, said gene comprising a nucleic acid sequence encoding a bacterial carboxypeptidase G which has been altered at one or more glycosylation sites to prevent glycosylation at said site or sites, together with a signal sequence, wherein upon expression of said gene in a eukaryotic tumor cell said signal sequence directs and tethers said bacterial carboxypeptidase G to the plasma membrane of said tumor cell, and, a prodrug which can be converted into an active drug by said bacterial carboxypeptidase G to provide a tumoricidal effect on said tumor.

17. The method of claim 16 wherein said tumor is a breast cancer.

18. The method of claim 16 wherein the prodrug is a nitrogen mustard prodrug.

19. A method of treating a breast tumor in a patient in need of treatment which method comprises administering to said patient an effective amount of a vector comprising a eukaryotic promoter operably linked to a gene, said gene comprising a nucleic acid sequence encoding a bacterial carboxypeptidase G which has been altered at one or more glycosylation sites to prevent glycosylation at said site or sites, together with a signal sequence, wherein upon expression of said gene in a eukaryotic tumor cell said signal sequence directs and tethers said bacterial carboxypeptidase G to the plasma membrane of said tumor cell, and, a nitrogen mustard prodrug which can be converted into an active drug by said bacterial carboxypeptidase G, said active drug having a tumoricidal effect on said breast tumor.

20. In a method of treatment of a tumor cell by gene-directed enzyme-prodrug therapy by delivering to a patient in need of treatment a gene which is expressed in the tumor to provide a gene product, and a prodrug which is converted to an active drug by said gene product, the improvement comprising expressing a gene which encodes a gene product comprising a bacterial carboxypeptidase G which has been altered at one or more glycosylation sites to prevent glycosylation at said site or sites, which gene product is transported to and tethered to the plasma membrane of the tumor cell and said active drug provides a tumoricidal effect on said tumor cell.

23. A vector comprising a eukaryotic promoter operably linked to a gene, said gene comprising a nucleic acid sequence encoding a bacterial carboxypeptidase G together with a signal sequence, wherein upon expression of said gene in a eukaryotic tumor cell said signal sequence directs and tethers said bacterial carboxypeptidase G to the plasma membrane of said tumor cell.